Advertisement

State of the Art of Antiemetic Therapy

  • Sonia Fatigoni
  • Fausto Roila
Chapter

Abstract

Despite relevant progress achieved in the last 30 years for the prevention of chemotherapy-induced emesis, nausea and vomiting continue to be among the most distressing adverse events induced by chemotherapy. Emesis is a complex phenomenon, and the precise mechanism by which chemotherapy induces nausea and vomiting is not well known. Many neurotransmitters are involved, and several antiemetic drugs are available. Complete control of vomiting could be achieved in about 70–90% of patients with a better combination of antiemetic drugs.

Recently, international guidelines to prevent chemotherapy-induced nausea and vomiting have been updated, and it is very important to know these recommendations and to use them correctly in our clinical practice. However, several aspects of antiemetic therapy will be clarified in the coming years: the improvement of nausea control, the prophylaxis of emesis induced by oral therapies, and the prevention of emesis induced by chemoradiation therapy.

Keywords

Antiemetics Chemotherapy Nausea Vomiting Side effects Chemoreceptor trigger zone (CTZ) 

References

  1. 1.
    Roila F, Malossotios A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119–33.CrossRefPubMedGoogle Scholar
  2. 2.
    MASCC/ESMO antiemetic guideline 2016. MASCC website saw in May 2nd, 2016.Google Scholar
  3. 3.
    Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189–98.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, et al. Antiemesis. J Natl Compr Cancer Netw. 2009;7:572–95. www.nccn.org CrossRefGoogle Scholar
  5. 5.
    Frame DG. Best practice management of CINV in oncology patients: physiology and treatment of CINV. J Support Oncol. 2010;8(Suppl 1):5–9.PubMedGoogle Scholar
  6. 6.
    Herrstedt J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol. 2007;101:143–50.CrossRefPubMedGoogle Scholar
  7. 7.
    Herrstedt J, Matti AS, John F. Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer. 1998;6:204–14.CrossRefPubMedGoogle Scholar
  8. 8.
    Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann Oncol. 2010;21:2316–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie MG, Eldridge K, Hipple A, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer. 2003;97:3090–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22):4112–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, et al. Comparison of an aprepitant regimen with multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high dose cisplatin treatment. Ann Oncol. 2006;17(6):1000.CrossRefPubMedGoogle Scholar
  12. 12.
    Kris MG, Tonato M, Bria E, Ballatori E, Espersen B, Herrstedt J, et al. Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer. 2011;19(Suppl 1):25–32.CrossRefGoogle Scholar
  13. 13.
    Grunberg SM, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, et al. Single-dose fosaprepitant for the prevention chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol. 2011;29:1495–501.CrossRefPubMedGoogle Scholar
  14. 14.
    Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25:1340–6.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015;16:1079–89.CrossRefPubMedGoogle Scholar
  16. 16.
    Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9:188–95.CrossRefPubMedGoogle Scholar
  17. 17.
    Abe M, Hirashima Y, Kasamatsu Y, et al. Efficacy and safety of olanzapine combined with aprepitant, palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1 phase II trial. Support Care Cancer. 2016;24:675–82.CrossRefPubMedGoogle Scholar
  18. 18.
    Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375:134–42.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Roila F, Ruggeri B, Ballatori E, et al. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Ann Oncol. 2015;26:1248–53.CrossRefPubMedGoogle Scholar
  20. 20.
    Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822–30.CrossRefPubMedGoogle Scholar
  21. 21.
    Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25:1328–33.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol. 2015;16:1071–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Roila F, Ruggeri B, Ballatori E, et al. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol. 2013;32:101–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Aapro M, Fabi A, Nolè F, Medici M, Steger G, Bachmann C, et al. Double-blind, randomized, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol. 2010;21(5):1083–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Celio L, Frustaci S, Denaro A, Buonadonna A, Ardizzoia A, Piazza E, et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, metacentre, phase III trial. Support Care Cancer. 2011;19:1217–25.CrossRefPubMedGoogle Scholar
  26. 26.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98:2473–82.CrossRefPubMedGoogle Scholar
  27. 27.
    Gralla R, Lichinitser M, Van der Vegt S, Sleeboom H, Mezger J, Peschel C, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10:115–24.CrossRefPubMedGoogle Scholar
  29. 29.
    Popovic M, Warr DG, Deangelis C, et al. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2014;22:1685–97.CrossRefPubMedGoogle Scholar
  30. 30.
    Yahata H, Kobayashi H, Sonoda K, et al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol. 2016;21:491–7.CrossRefPubMedGoogle Scholar
  31. 31.
    The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med. 2000;342:1554–9.CrossRefGoogle Scholar
  32. 32.
    Feyer PC, Maranzano E, Molassiotis A, Roila F, Clark-Snow RA, Jordan K, et al. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer. 2011;19(suppl 1):5–14.CrossRefGoogle Scholar
  33. 33.
    Einhorn LH, Grunberg SM, Rapoport B, Rittenberg C, Feyer P. Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer. 2011;19(suppl 1):1–4.CrossRefGoogle Scholar
  34. 34.
    Albany C, Brames MJ, Fausel C, et al. Randomized double-blind placebo controlled phase III crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5 day-cisplatin combination chemotherapy regimens: a Hoosier Oncology Group (HOG) study. J Clin Oncol. 2012;30:3998–4003.CrossRefPubMedGoogle Scholar
  35. 35.
    Boccia RV, Gordan LN, Clark G, et al. Sancuso Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011;19:1609–17.CrossRefPubMedGoogle Scholar
  36. 36.
    Stiff PJ, Fox-Geiman MP, Kiley K, et al. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant. 2013;19:49–55.CrossRefPubMedGoogle Scholar
  37. 37.
    Schmitt T, Goldschmidt H, Neben K, et al. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol. 2014;32:3413–20.CrossRefPubMedGoogle Scholar
  38. 38.
    Navari RM, Nagy CK, Gray SE, et al. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supp Care in Cancer. 2013;21:1655–63.CrossRefGoogle Scholar
  39. 39.
    Chanthawong S, Subongkot S, Sookprasert A, et al. Effective of olanzapine for the treatment of breakthrough chemotherapy-induced nausea and vomiting. J Med Assoc Thail. 2014;97:349–55.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of OncologySanta Maria HospitalTerniItaly

Personalised recommendations